In An Inorganic Compound Patents (Class 424/1.61)
-
Patent number: 7803350Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.Type: GrantFiled: July 30, 2007Date of Patent: September 28, 2010Assignees: Institute of Nuclear Energy Research Rocaec, TTY Biopharm Company, LimitedInventors: Te-Wei Lee, Chun-Ying Huang, Ming-Shiuan Wu, Te-Jung Chen, Kwo-Ping Chang, Shiang-Rong Chang, Shyh-Yi Chyi, Chih-Hsien Chang, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao
-
Publication number: 20100233081Abstract: A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent.Type: ApplicationFiled: May 9, 2008Publication date: September 16, 2010Applicant: PEAK BIOSCIENCE, INC.Inventors: Stephen L. Warren, James E. Matsuura, Michael J. Gerber
-
Patent number: 7785569Abstract: A standardized, lyophilized edible food containing a biologically safe stable marker for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient.Type: GrantFiled: May 9, 2003Date of Patent: August 31, 2010Assignee: Advanced Breath Diagnostics, LLCInventors: Keith Darrel Evans, Stanley John Konopka, Kerry Clepper Bush
-
IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS
Publication number: 20100215573Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.Type: ApplicationFiled: July 25, 2008Publication date: August 26, 2010Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Publication number: 20100196268Abstract: This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used. Administration of the dose for bone cancer may be done through a hole or multiple holes created in the bone using a miniature drill. Delivery of the dose directly into a tumor may be accomplished using a microsyringe or a miniature pump capable of accurately delivering microliter amounts of material.Type: ApplicationFiled: April 5, 2010Publication date: August 5, 2010Applicants: IsoTherapeutics Group LLC, Gabriel Institute, Inc.Inventors: R. Keith Frank, Kenneth McMillan, Jaime Simon, H.Max Loy, JR., Stanley D. Stearns, Edna Sue McMillan
-
Publication number: 20100166653Abstract: Compositions of high specific activity 117mSn with specific activity of greater than 100 Ci/g Sn and methods of producing the same. The method includes exposing 116Cd to an ?-particle beam of sufficient incident kinetic energy and duration to convert a portion of the 116Cd to 117mSn to form an irradiated material. The irradiated material is dissolved to form an intermediate solution containing 117mSn and 116Cd. The 117mSn is separated from the 116Cd to yield high specific activity 117mSn.Type: ApplicationFiled: December 26, 2008Publication date: July 1, 2010Applicant: CLEAR VASCULAR, INC.Inventors: Nigel Raymond Stevenson, Ian Martin Horn
-
Publication number: 20100168554Abstract: Methods suitable for use in diagnostic imaging or to generate a central circulatory turnover (CCT) index for an evaluation of cardiac function of a patient are provided. The resultant CCT index will allow the clinician to integrate information reflecting the diastolic function of the heart. A computer software and kit for the evaluation of cardiac function in a patient as well as the use of a CCT index for an evaluation of cardiac function of a patient are also provided.Type: ApplicationFiled: June 30, 2006Publication date: July 1, 2010Inventor: Jens Sorensen
-
Publication number: 20100150830Abstract: A method and composition for administering a therapeutic agent to a lesion comprising a contrast/carrier agent and ethanol.Type: ApplicationFiled: November 21, 2008Publication date: June 17, 2010Inventor: Chun Ho Yu
-
Patent number: 7736848Abstract: Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.Type: GrantFiled: March 30, 2005Date of Patent: June 15, 2010Assignee: Fox Chase Cancer CenterInventors: Rene Daniel, Anna Marie Skalka, Gary D. Kao, Giuseppe Nunnari, Roger J. Pomerantz
-
Publication number: 20100143247Abstract: The present invention provides a method for determining the presence of prostate cancer in a subject which method comprises determining the level of expression of one or more markers in a blood sample from the subject, wherein said one or more markers comprise at least one of E2F3, c-met, pRB, EZH2, e-cad, CAXII, CAIX, HIF-1?, Jagged, PIM-1, hepsin, RECK, Clusterin, MMP9, MTSP-1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, Kallikrein 2, Kallikrein 3 and PSGR.Type: ApplicationFiled: November 24, 2005Publication date: June 10, 2010Applicant: St. George's Enterprises LimitedInventors: Christiane Dorothea Fenske, Sabarinath Balachandran Nair, Christodoulos Pipinikas, Nicholas David Carter
-
Publication number: 20100135903Abstract: The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a metastatic neoplastic tumour in a localised manner by effecting the exposure of neoplastic cell intra-cellular molecules, preferably intra-nuclear molecules, suitable for use as a therapeutic target. The co-localisation of tumour cells and metastases to discrete tissue locations thereby renders the method of the present invention useful in terms of the delivery of bystander-based therapy.Type: ApplicationFiled: October 11, 2007Publication date: June 3, 2010Applicant: MEDVET SCIENCE PTY. LTD.Inventors: Michael Paul Brown, Fares Al-Ejeh, Jocelyn Margaret Darby
-
Patent number: 7722857Abstract: An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity.Type: GrantFiled: January 6, 2006Date of Patent: May 25, 2010Assignee: Cell-Medicine, Inc.Inventors: Tadao Ohno, Eiji Uchimura
-
Patent number: 7718160Abstract: The invention, in one aspect, relates to radiolabeled compounds. The invention also relates to radiolabeled liposomes and methods of making and using thereof. The invention also relates to kits for preparing radiolabeled liposomes.Type: GrantFiled: May 22, 2003Date of Patent: May 18, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Ande Bao, William T. Phillips, Beth Goins
-
Publication number: 20100111857Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: February 26, 2009Publication date: May 6, 2010Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Patent number: 7708987Abstract: The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting the immune system of the mammal and, concurrently or subsequently, administering to the proliferating cells an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells. In particular, the methods provide for reovirus treatment of immunosuppressed or immuno-deficient mammals to treat the proliferative disorders. Immunosuppression, immunoinhibition or otherwise inducing an immunodeficient state in a mammal renders the reovirus more effective.Type: GrantFiled: May 30, 2007Date of Patent: May 4, 2010Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Publication number: 20100076489Abstract: Articles are provided having no orientation or a multi-directional orientation. Such articles may be in the form of films, ribbons, sheets, and/or tapes and may be utilized as buttresses with a surgical stapling apparatus or as reinforcing means for suture lines. The articles may be produced with a polymeric material having an agent, such as a chemotherapeutic agent or a radiotherapeutic agent, incorporated therein or applied as a coating thereon.Type: ApplicationFiled: March 31, 2009Publication date: March 25, 2010Inventors: Joshua Stopek, Amin Elachchabi, Roland Ostapoff, Brian Nentwick, Richard Stevenson
-
Publication number: 20100015048Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.Type: ApplicationFiled: September 3, 2009Publication date: January 21, 2010Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20100008854Abstract: The disclosure provides metal nanocomposites including one or more metal nanoparticles having a hydrophobic surface and at least partially enclosed by cationic and hydrophilic polymers. The metal nanocomposites are useful as among others, a contrast agent, a diagnostic composition or a pharmaceutical composition.Type: ApplicationFiled: July 11, 2008Publication date: January 14, 2010Inventors: Seung Joo Haam, Sung Baek Seo, Jae Moon Yang
-
Publication number: 20090324493Abstract: The invention relates to a method for preparing a saline solution comprising [13N]NH4+. The method comprises following steps: preparing [13N]NH3 gas, transporting [13N]NH3 gas to a diffusion chamber, to a first side of a semipermeable membrane, transporting sterile saline solution to the diffusion chamber, to a second side of a semipermeable membrane, allowing the mixing of [13N]NH3 gas that has penetrated the semipermeable membrane with the saline solution on the second side of the semipermeable membrane, whereby saline solution comprising [13N]NH4+ is obtained, and directing the saline solution comprising [13N]NH4+ out from the diffusion chamber. The invention relates also to use of a device for preparing a radiolabelled saline solution for preparation of a saline solution comprising [13N]NH4+.Type: ApplicationFiled: April 25, 2006Publication date: December 31, 2009Applicant: HIDEX OYInventors: Paul Burke, Hannu Sipilä, John Charles Clark
-
Publication number: 20090317325Abstract: The present invention relates to a diagnostic substance, containing at least one complex of lipophilic anions and metal ions, wherein the lipophilic anions are selected from the group comprising: triethylene tetramine dihydrochloride (TETA), ethyl cysteinate dimer (ECD), methoxyisobutylisonitrile (MIBI), HMPAO (d,l-hexamethylpropylene aminoxime), ethylenediamine N,N,N?,N?-tetraacetanilide (EDTAN), dimethyldithiocarbamate (DMC) and diethyldithiocarbamate (DDC) and glycine N,N?-[1,2-ethanediylbis(oxy-2,1-phenylene)]bis [N-(carboxymethyl)-1,1?-bis[2-(octadecyloxy)ethyl]ester (DP-109), and wherein the metal ions are selected from the group comprising thallium isotopes, lead isotopes, cobalt isotopes and manganese isotopes, together with solvents, adjuvants and/or vehicles. The diagnostic substance is used for investigating metabolic processes in the brain and/or central nervous system (CNS).Type: ApplicationFiled: December 29, 2006Publication date: December 24, 2009Inventors: Iryna Ziabreva, Petra Henrich-Noack, Juergen Goldschmidt, Kathrin Baldauf, Henning Scheich, Klaus G. Reymann, Ulrich H. Schroeder, Claudia Pforte, Monika Riek-Burchardt
-
Publication number: 20090311175Abstract: The invention provides methods for enhancing iodine absorption in a thyroid in a subject and treating thyroid cancer by administering to the subject a composition which includes a multi-kinase inhibitor. Furthermore, the invention provides methods for improving a medical diagnostic procedure based on radioactive iodine in a subject by administering to the subject a composition comprising a multi-kinase inhibitor.Type: ApplicationFiled: May 7, 2009Publication date: December 17, 2009Inventor: Marcia S. Brose
-
Publication number: 20090304582Abstract: Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence: (a) administering to a subject about 3 mCi Tl201 thallous chloride; (b) allowing said subject to rest; (c) radioimaging a heart of said subject; (d) subjecting said subject to a physical stress; (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.Type: ApplicationFiled: July 19, 2006Publication date: December 10, 2009Applicant: SPECTRUM DYNAMICS LLCInventors: Benny Rousso, Dalia Dickman, Yael Nir, Michael Nagler, Zohar Bronshtine, Shankar Vallabhajosula, Shlomo Ben-Haim, Simona Ben-Haim
-
Publication number: 20090297442Abstract: The present invention relates to improved radiopharmaceutical compositions in sealed containers, where the container closure has an ETFE (ethylene-tetrafluoroethylene copolymer) coating. Also disclosed are kits for radiopharmaceutical preparation using the sealed containers, as well as methods of preparation of radiopharmaceuticals using the sealed containers.Type: ApplicationFiled: June 21, 2007Publication date: December 3, 2009Inventor: Stig Hemstad
-
Publication number: 20090297441Abstract: The use of silicon as an imaging agent is described.Type: ApplicationFiled: September 22, 2006Publication date: December 3, 2009Inventors: Leigh Trevor Canham, Anna Agnieszka Kluczewska, Jerome Paul Barley, Raphaela Fortes Drummond Chicarino Varajao
-
Publication number: 20090285750Abstract: The present application relates to agents, compositions and methods for use in medicine. In particular, the application relates to an agent comprising a binding moiety capable of selectively binding to Ku protein for use in medicine, in particular in the treatment and diagnosis of cancers.Type: ApplicationFiled: April 11, 2007Publication date: November 19, 2009Inventors: Carl Borrebaeck, Johan Fransson
-
Publication number: 20090263319Abstract: Methods and compositions are provided for reducing, treating or preventing postoperative pain or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of ketorolac or pharmaceutically acceptable salt thereof to a target tissue site, wherein the drug depot releases an effective amount of ketorolac or pharmaceutically acceptable salt thereof over a period of 3 to 10 days.Type: ApplicationFiled: February 19, 2009Publication date: October 22, 2009Applicants: Warsaw Orthopedic, Inc., Medtronic Inc.Inventors: Amira Wohabrebbi, William F. McKay, Christopher M. Hobot, Keith R. Hildebrand, Edward Phillip McDonald
-
Publication number: 20090257949Abstract: Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein.Type: ApplicationFiled: April 3, 2009Publication date: October 15, 2009Applicant: AVID RADIOPHARMACEUTICALS, INC.Inventors: Franz F. Hefti, Daniel M. Skovronsky, Alan P. Carpenter, JR.
-
Publication number: 20090246126Abstract: A capsule for high dose rate brachytherapy, wherein the capsule comprises within its interior space thulium-170, and further comprises at least one layer of a radiation emission modifying metal (e.g., gold), wherein said layer is provided either internally within the capsule or on the outer surface thereof.Type: ApplicationFiled: April 1, 2009Publication date: October 1, 2009Applicant: Ben-Gurion University of the Negev Research and Development AuthorityInventor: Gad Shani
-
Publication number: 20090202434Abstract: The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. The present invention also refers to a wound dressing for treating skin lesion, comprising the pharmaceutical composition of the present invention. The present invention further refers to the use of a cerium salt associated with collagen in the preparation of the pharmaceutical composition or wound dressing according to the present invention.Type: ApplicationFiled: September 2, 2008Publication date: August 13, 2009Inventor: Luis Eduardo da Cruz
-
Publication number: 20090191122Abstract: The present invention describes a method for purification of 225Ac from irradiated 226Ra-targets provided on a support, comprising a leaching treatment of the 226Ra-targets for leaching essentially the entirety of 225Ac and 226Ra with nitric or hydrochloric acid, followed by a first extraction chromatography for separating 225Ac from 226Ra and other Ra-isotopes and a second extraction chromatography for separating 225Ac from 210Po and 210Pb. The finally purified 225Ac can be used to prepare compositions useful for pharmaceutical purposes.Type: ApplicationFiled: February 19, 2007Publication date: July 30, 2009Applicant: ACTINIUM PHARMACEUTICALS INC.Inventors: Josue Manuel Moreno Bermudez, Andreas Turler, Richard Henklemann, Eva Kabai, Ernst Huenges
-
Publication number: 20090155167Abstract: The present invention provides an automated method for the preparation of 99mTc radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation of 99mTc radiopharmaceuticals is also described. Also described is the use of kits for the preparation of 99mTc radiopharmaceuticals in the method and disposable cassettes of the present invention.Type: ApplicationFiled: October 9, 2006Publication date: June 18, 2009Applicant: GE HEALTHCARE LIMITEDInventors: Nigel Anthony Powell, Peter Stewart Weisner, Ian Anthony Sargeant, Torgrim Engell, John Henrik Johansen
-
Publication number: 20090117039Abstract: In accordance with one aspect of the invention, implantable medical devices are provided which include polymeric compositions that comprise at least one type of biodegradable ionic polymer. The at least one type of biodegradable ionic polymer comprises a biodegradable polymer core and one or more ionic end groups.Type: ApplicationFiled: October 31, 2008Publication date: May 7, 2009Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventor: Robert E. Richard
-
Publication number: 20090028787Abstract: The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: ApplicationFiled: January 25, 2007Publication date: January 29, 2009Inventors: Ylva Gravenfors, Catrin Jonasson, Jonas Malmstrom, Gunnar Nordvall, David Pyring, Can Slivo, Daniel Sohn, Peter Strom, David Wensbo
-
Publication number: 20090022655Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.Type: ApplicationFiled: April 30, 2008Publication date: January 22, 2009Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birls, Richard Beger
-
Publication number: 20080286200Abstract: A standardized, lyophilized edible food containing a biologically safe stable marker for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient.Type: ApplicationFiled: May 15, 2008Publication date: November 20, 2008Applicant: Advanced Breath Diagnostics, LLCInventors: Kerry C. Bush, Keith D. Evans, Stanley J. Konopka
-
Kit for preparation of nano-targeted liposome drug in combined radionuclide therapy and chemotherapy
Publication number: 20080226546Abstract: This invention is to manufacture a kit for preparation of nano-targeted liposome drugs in combined chemotherapy and radionuclide therapy. It is a kit consisting of three components: (1) A 10 ml vial A which contains BMEDA, gluconate acetate, SnCl2. (2) A 10 ml vial B which contains DSPC, cholesterol, DSPE-PEG, and Doxorubicin(DXR) (or Daunorubicin, Vinolbine). (3) A 10 ml vial C which contains 188ReO4? (or 186ReO4?) solution. The procedure of using the kit is as follows: (1) Remove the contents of the 188ReO4? (or 186ReO4?) solution from vial C. (2) Inject the 188ReO4? (or 186ReO4?) solution into the vial A, and the mixtures react in appropriate temperature. (3) Remove the contents of the 188Re-BMEDA (or 186Re-BMEDA) solution from vial A. (4) Inject the 188Re-BMEDA (or 186Re-BMEDA) solution into the vial B, and the mixtures react in appropriate temperature. The reconstituted solution in the vial B is applied to combine bimodality radiochemotherapy for treatment of tumor and ascites.Type: ApplicationFiled: March 18, 2007Publication date: September 18, 2008Inventors: Te-Wei Lee, Ya-Jen Chang, Liang-Cheng Chen, Chia-Yu Yu, Shu-Pei Chiu, Shu-Ling Chen, Tsai-Yueh Luo, Chih-Hsien Chang, Gann Ting -
Publication number: 20080226547Abstract: The present invention provides Hydroxyapatite (HA) incorporating an alpha-emitting radionuclide or an in vivo generator for an alpha-emitting radionuclide. The invention further provides methods for the formation of such HA, pharmaceutical compositions comprising the HA and methods of medical treatment of cancerous or noncancerous disease including administering the HA or compositions thereof.Type: ApplicationFiled: February 18, 2005Publication date: September 18, 2008Inventors: Roy H. Larsen, Gro Salberg
-
Publication number: 20080226549Abstract: A method of treating breast cancer that is at least partially ER+ is disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.Type: ApplicationFiled: November 28, 2007Publication date: September 18, 2008Applicant: Signe Biopharma Inc.Inventor: David Sirbasku
-
Publication number: 20080213172Abstract: Conjugates, methods and kits are described for imaging tissues and organs that express one or more peptidases. In a preferred embodiment of the invention, a series of di-(2-pyridylmethyl)amine (D) ligands, which can bind M(CO)3+ [M=Tc or Re], were coupled to lisinopril (L). Aliphatic tethers with varying number of methylene groups (3, 4, 5, and 7; D(C4)L, D(C5)L, D(C6)L, and D(C8)L, respectively) were utilized, with in vitro inhibitory activity increasing with increasing number of methylene groups. The D(C8)L conjugate was observed to be significantly more potent than D(C4)L. In vivo specificity for ACE was studied in both tissue distribution and gamma imaging studies, demonstrating localization in tissues with high ACE content. Localization was blocked by pretreatment with lisinopril.Type: ApplicationFiled: August 29, 2007Publication date: September 4, 2008Inventors: J. W. Babich, W. C. Eckelman, F. J. Femia, Craig Zimmerman
-
Publication number: 20080206134Abstract: A radiographic composition for promoting the formation of clots in blood includes a zeolite and iodine. A device for promoting the clotting of blood at an internal wound site includes a catheter; a delivery instrument insertable through the catheter; a radioopaque blood clotting agent that deliverable through the delivery instrument; and a positive pressure apparatus that can dispense the blood clotting agent to the wound site through the delivery instrument. A system for radiographically imaging an internally bleeding wound includes means for delivering a radioopaque blood clotting agent and means for radiographically imaging the radioopaque blood clotting agent. A method of imaging an internally bleeding wound includes the steps of inserting a catheter into a patient; advancing the catheter to a point adjacent the bleeding wound; depositing a radioopaque zeolite at the bleeding wound; and imaging the radioopaque zeolite to monitor blood-clotting caused by the zeolite.Type: ApplicationFiled: February 22, 2007Publication date: August 28, 2008Inventors: Denny Lo, Giacomo Basadonna
-
Publication number: 20080193376Abstract: The present invention relates to methods for the detection and therapy of active atheromatous plaques, and in particular vulnerable plaques, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by the inflammatory cells associated with such plaques.Type: ApplicationFiled: October 28, 2004Publication date: August 14, 2008Applicant: The General Hospital CorporationInventors: Ahmed Tawakol, Michael R. Hamblin, Raymond Q. Migrino, Jeffrey Gelfand
-
Publication number: 20080187489Abstract: A generator that allows for a non-fission based method of producing and recovering 99mTc from neutron-irradiated molybdenum. This generator system is based on the isolation of 99mTc, as the decay product from a source of 99Mo labelled molybdenum carbonyl Mo(CO)6 through a distillation process. The 99mTc obtained from this distillation is produced with high efficiency and purity in a solvent-free form, which can then be dissolved in water or other solvents to produce a solution at the required specific activity and concentration, as reasonably determined by the operator.Type: ApplicationFiled: October 6, 2005Publication date: August 7, 2008Applicant: MCMASTER UNIVERSITYInventors: Richard Tomlison, Bruce Collier, Alan Guest
-
Publication number: 20080138277Abstract: The invention relates to the treatment and prevention of atherosclerosis and cardiovascular diseases associated with atherosclerosis. The invention further relates to methods of diagnosing atherosclerosis and cardiovascular diseases associated with atherosclerosis. In certain embodiments, the invention provides biological systems and methods for delivering a therapeutic agent or an imaging agent to atherosclerotic lesions such as vulnerable plaques.Type: ApplicationFiled: March 23, 2006Publication date: June 12, 2008Applicants: MEDSTAR HEALTH INC, Georgetown UniversityInventors: Stephen E. Epstein, Mary Susan Burnett, Martin A. Mullins
-
Patent number: 7364859Abstract: Bioelastomers are disclosed for use in methods of binding compounds including immunoassay methods, in biosensors and methods or regenerating biosensors, and in methods for targeting the delivery of a compound to a particular location within an animal subjects. In general, the bioelastomer is conjugated to a binding compound, which is in turn used to bind a compound of interest. For targeted compound delivery, the bioelastomer is conjugated to the compound to be delivered.Type: GrantFiled: July 31, 2002Date of Patent: April 29, 2008Assignee: Duke UniversityInventor: Ashutosh Chilkoti
-
Patent number: 7357913Abstract: The invention relates to techniques for measuring and comparing relative molecular flux rates of different biological molecules by administering isotope-labeled water to one or more tissues or individuals and comparing the molecular flux rates of two or more biological molecules, including biological molecules in different chemical classes. The methods find use in several applications including diagnosing, prognosing, or monitoring a disease, disorder, or condition, the in vivo high-throughput screening of chemical entities and biological factors for therapeutic effects in various disease models, and the in vivo high-throughput screening of chemical entities and biological factors for toxic effects.Type: GrantFiled: May 11, 2006Date of Patent: April 15, 2008Assignee: The Regents of the University of CaliforniaInventor: Marc K. Hellerstein
-
Patent number: 7329400Abstract: Radioisotope generators comprising inorganic layered hydroxide composition, such as magnesium aluminates and lithium aluminates. These inorganic layered hydroxides form anion exchange materials that exhibit surprisingly high selective affinities for certain radioisotopes. Inorganic layered hydroxides have been prepared and shown to have high affinity for tungstate anions, the anion form of tungsten-188, yet low affinity for perrhenate anions, the anion form of rhenium-188.Type: GrantFiled: June 19, 2002Date of Patent: February 12, 2008Assignee: Lynntech, Inc.Inventors: Alan Cisar, Todd Adams, Paul Sylvester
-
Patent number: 7265199Abstract: The present invention relates to an anti-thrombogenic, physically well-tolerated polymer and its use for manufacturing sheaths and films as a component of therapeutic devices for preventing excessive cell proliferation. Furthermore, it relates to films made from the polymer as well as wrappings for medical devices such as stents. It also relates to medical devices that are enclosed by a film or wrapping according to the invention.Type: GrantFiled: April 10, 2001Date of Patent: September 4, 2007Assignee: Celonova BioSciences Germany GmbHInventors: Michael Grunze, Claudia Gries
-
Patent number: 7194360Abstract: A method of simply and quickly determining ?-ray releasing nuclides having long half-life without carrying out a chemical separation is provided. By inputting a data of pulses incident to an ?-ray detector in a computer, obtaining time distribution of the incident pulses by using a very short time measuring timer and plotting, and fitting the linear originated in a random event corresponding to the background and the non-linear originated in the correlated events of parent nuclides-progenies by using the least squares method, the whole generating probability P (t) from the parent nuclide to the progeny thereof is obtained. By subtracting the random events portion from the P(t), the correlated events portion is extracted. The radioactivity per unit can be obtained by dividing the extracted correlated events portion by the measured time, the amount of the supplied sample and the counting efficiency.Type: GrantFiled: September 23, 2003Date of Patent: March 20, 2007Assignee: Japan Nuclear Cycle Development InstituteInventors: Yasuhiro Uezu, Tetsuo Hashimoto
-
Patent number: 7150867Abstract: This invention relates to a particulate material comprising an inorganic low density, radiation tolerant core coated with a radionuclide, processes for its production and a method of radiation therapy utilizing the particulate material.Type: GrantFiled: June 17, 2002Date of Patent: December 19, 2006Assignee: Sirtex Medical LimitedInventors: Andrew John Ruys, Bruce Andrew Gray
-
Patent number: 7018609Abstract: The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent.Type: GrantFiled: December 19, 2001Date of Patent: March 28, 2006Assignees: California Institute of Technology, Insert Therapeutics, Inc.Inventors: Suzie Hwang Pun, Hector Gonzalez, Mark E. Davis, Nathalie Bellocq, Jianjun Cheng